CymaBay Therapeutics (CymaBay Therapeutics) Debt-to-Equity : 0.39 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics Debt-to-Equity?

CymaBay Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.01 Mil. CymaBay Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $104.49 Mil. CymaBay Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $292.26 Mil. CymaBay Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.39.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CymaBay Therapeutics's Debt-to-Equity or its related term are showing as below:

CBAY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.33 Max: 2.52
Current: 0.39

During the past 12 years, the highest Debt-to-Equity Ratio of CymaBay Therapeutics was 2.52. The lowest was 0.01. And the median was 0.33.

CBAY's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs CBAY: 0.39

CymaBay Therapeutics Debt-to-Equity Historical Data

The historical data trend for CymaBay Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CymaBay Therapeutics Debt-to-Equity Chart

CymaBay Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.39

2.52

0.39

CymaBay Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															2.52	0.91	0.92	0.32	0.39

Competitive Comparison of CymaBay Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, CymaBay Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CymaBay Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CymaBay Therapeutics's Debt-to-Equity falls into.

CymaBay Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CymaBay Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.007	+	104.487)	/	292.256
	=	0.39

CymaBay Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.007	+	104.487)	/	292.256
	=	0.39

CymaBay Therapeutics (NAS:CBAY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CymaBay Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

C0I:Germany

Address

7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560

Website

https://www.cymabay.com

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

Executives

Charles Mcwherter	officer: Chief Scientific Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold	officer: Vice President, Finance	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan	officer: General Counsel	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling	director	C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah	director, officer: Chief Executive Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster	director	601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam	officer: Chief Financial Officer	7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim	officer: Chief Medical Officer	C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans	director
Lewis J Stuart	officer: Chief Commercial Officer	3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc	10 percent owner	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh	10 percent owner	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer	director	161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills	director	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103